Trinity Biotech (TRIB) Convertible Debt (2021 - 2025)

Trinity Biotech (TRIB) has reported Convertible Debt for 5 consecutive years, with $15.9 million the latest figure, recorded in Q2 2025.

• Quarterly Convertible Debt rose 5.97% year-over-year to $15.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $15.9 million (up 5.97% YoY) and the FY2024 annual result came in at $15.4 million, up 5.91% from the prior year.
• Convertible Debt advanced to $15.9 million in Q2 2025 per TRIB's latest filing, from $15.4 million in the prior quarter.
• Over the last five years, Convertible Debt for TRIB reached as high as $83.3 million in Q4 2021 and fell as low as $13.4 million in Q2 2022.
• A 5-year average of $19.8 million and a median of $14.5 million in 2023 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2022 — Convertible Debt sank 83.5% — and 2025, when it climbed 5.97%.
• Year by year, Convertible Debt stood at $83.3 million in 2021, then plunged by 83.5% to $13.7 million in 2022, then gained by 5.79% to $14.5 million in 2023, then grew by 5.91% to $15.4 million in 2024, then climbed by 2.96% to $15.9 million in 2025.
• According to Business Quant data, Convertible Debt over the past three periods registered $15.9 million, $15.4 million, and $15.2 million for Q2 2025, Q4 2024, and Q3 2024 respectively.